#7 - Xenon Pharmaceuticals (XENE) (NASDAQ:XENE)
Could I interest you in a stock that gapped up nearly 100% at one point in 2021? That was the case with Xenon Pharmaceuticals (NASDAQ: XENE) that made a substantial move after announcing positive mid-stage clinical trial results for its drug candidate designed to treat adult patients with focal epilepsy.
The drug, XEN1101 is part of what is being considered the “next generation” of epilepsy drugs. And the key is that these drugs are expected to deliver improved effectiveness with fewer side effects that are common with current epilepsy drugs.
It’s not wise to chase a stock that nearly doubled in so short a period of time. And Xenon is a low revenue company that has never seen its stock climb to this level since it went public in 2014. If you don’t currently have a position in XENE stock, you might wait until after the company delivers earnings in early November. This will give investors a better line of sight of when the company will be ready to bring XEN1101 to market.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Read More - Current Price
- $41.15
- Consensus Rating
- Buy
- Ratings Breakdown
- 12 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $57.45 (39.6% Upside)
In investing, catching a hot stock can be intoxicating, but it’s usually best to take the long view. As more becomes known about the novel coronavirus, science is adapting – which is what science does. The reality of Covid-19 is becoming one of a virus that will need to be managed as opposed to eradicated. The good news is that managing illnesses falls into the pharmaceutical sector’s wheelhouse. And there are companies that are working to do just that.
This is a story that will play out over a long time. And several of the companies in this presentation will be among the leaders in making that happen.
But one of the appealing features of investing in the pharmaceutical sector is that investors can find value in other areas. For example, in 2022, there are likely to be breakthroughs in areas like oncology and diabetes. Those will provide additional catalysts for pharmaceutical stocks some of which we’ve listed here as well.
More Investing Slideshows:
